BioLineRx (NASDAQ:BLRX) is up 21% premarket on the heels of updated data from the triple combination arm of the ongoing Phase 2a COMBAT/KEYNOTE-202 study.
The triple combination arm focuses on second-line pancreatic cancer patients and is expected to include approx. 40 patients originally diagnosed with unresectable metastatic pancreatic adenocarcinoma who have progressed following first-line gemcitabine-based therapy. As of today’s date, 36 out of 40 patients have been enrolled.
An overall response rate (ORR) of 32% and a disease control rate (DCR) of 77% was observed compared to the current chemotherapy standard-of-care treatment in second-line patients with ORR of 17% and DCR of 52%.
Out of the 7 partial responders, 4 responders showed a reduction in tumor burden of >50%.
Median duration of clinical benefit until progression for the 17 patients with disease control is 7.8 months.
Progression-free and overall survival data remain on track for mid-2020.
The combination was generally well tolerated.
Previously: BioLineRx reports interim data on BL-8040 combo in pancreatic cancer (Dec. 5)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.